Promomed

Promomed is a Russian pharmaceutical company engaged in the development, production, research and distribution of medicines. The company's main production site is the Biochemik plant in Saransk.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Promomed balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Promomed cash flows

Report period2019 2020 2021 2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Promomed multipliers

Report period2019 2020 2021 2022 2023 Q2 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Promomed profitability

Report period2019 2020 2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Promomed assets
Promomed cash flows

Promomed dividend policy

The amount of dividends is determined based on the following ratio: Net Debt / Adj. EBITDA ≤ 1 - at least 50% of Adj. earnings; 1 < Net Debt / Adj. EBITDA ≤ 2 - at least 25% of Adj. earnings; 2 < Net Debt / Adj. EBITDA ≤ 2.5 - at least 15% of Adj. earnings. The basis for calculation is IFRS reporting.

Promomed shares

TickerNameTypeNominal valueISINPrice
PRMD:RMPromomedCommon shareRUB 1RU000A108JF7RUB 298

Promomed bonds

NameIssue sizePriceYield
PROMOMED DM 002P-01 (RUB)3,500,000 pcs.86.39%21.86%
PROMOMED DM 001P-03 (RUB)2,500,000 pcs.100%8.69%
PROMOMED DM 001P-01 (RUB)1,000,000 pcs.100.02%0.08%
PROMOMED DM 001P-02 (RUB)977,896 pcs.99.96%0.05%
Share capital structure of Promomed
Promomed news
02.12.2024
Promomed's revenue for 9 months of 2024 amounted to ₽10.7 billion, up 34% year-on-year. In the endocrinology segment, revenue increased by 49% to ₽3.1 billion. Oncology sales grew by 58% to ₽2.5 billion.
Source: promomed.ru
Pictogram next
25.10.2024
Promomed's RAS loss for 9 months of 2024 amounted to ₽55.8 million, up 60.8% from ₽34.7 million in the previous year. Revenue was not disclosed by the company.
Source: {source} pictogram e-disclosure.ru
Pictogram next
04.10.2024
Promomed launches a new drug Velgia for the treatment of overweight and obesity of any severity. Registration procedure for the drug, produced on a full cycle from substance to finished dosage form, has been completed. First batches will go on sale in Q4 2024.
Source: promomed.ru
Pictogram next
29.08.2024
Promomed's IFRS net profit for 6 months of 2024 amounted to ₽5.08 millions, down multiple times from ₽464.93 millions in the previous year. Revenue increased 22.1% to ₽7.13 billion versus ₽5.84 billion a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
All Promomed news
General information
Company namePromomed
Tags#biotechnology, #pharmacy, #ipo2024
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressMoskva, prospekt Mira, dom 13, stroenie 1
Mailing address129090, g. Moskva, prospekt Mira, dom 13, stroenie 1, etazh 2, pomeschenie 5
Websitepromomed.ru
Information disclosuree-disclosure.ru